TITLE

Human Papillomavirus Detection from Human Immunodeficiency Virus-Infected Colombian Women's Paired Urine and Cervical Samples

AUTHOR(S)
Munoz, Marina; Camargo, Milena; Soto-De Leon, Sara C.; Sanchez, Ricardo; Parra, Diana; Pineda, Andrea C.; Sussmann, Otto; Perez-Prados, Antonio; Patarroyo, Manuel E.; Patarroyo, Manuel A.
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Infection, coinfection and type-specific human papillomavirus (HPV) distribution was evaluated in human immunodeficiency virus (HIV)-positive women from paired cervical and urine samples. Paired cervical and urine samples (n = 204) were taken from HIV-positive women for identifying HPV-DNA presence by using polymerase chain reaction (PCR) with three generic primer sets (GP5+/6+, MY09/11 and pU1M/2R). HPV-positive samples were typed for six high-risk HPV (HR-HPV) (HPV-16, -18, -31, -33, -45 and -58) and two low-risk (LR-HPV) (HPV-6/11) types. Agreement between paired sample results and diagnostic performance was evaluated. HPV infection prevalence was 70.6% in cervical and 63.2% in urine samples. HPV-16 was the most prevalent HPV type in both types of sample (66.7% in cervical samples and 62.0% in urine) followed by HPV-31(47.2%) in cervical samples and HPV-58 (35.7%) in urine samples. There was 55.4% coinfection (infection by more than one type of HPV) in cervical samples and 40.2% in urine samples. Abnormal Papanicolau smears were observed in 25.3% of the women, presenting significant association with HPV-DNA being identified in urine samples. There was poor agreement of cervical and urine sample results in generic and type-specific detection of HPV. Urine samples provided the best diagnosis when taking cytological findings as reference. In conclusion including urine samples could be a good strategy for ensuring adherence to screening programs aimed at reducing the impact of cervical cancer, since this sample is easy to obtain and showed good diagnostic performance.
ACCESSION #
87624677

 

Related Articles

  • Smear Campaign.  // Working Mother;Apr2002, p18 

    Reports the endorsement of the Human Papilloma Virus (HPV) test by the American Medical Women's Association. Detection of the human papillomavirus; Comparison of the technique with Paps smear; Use of HPV test for early detection of cervical cancer.

  • Study Results Help Define HPV's Role As Diagnostic Tool. Arnold, Katherine // JNCI: Journal of the National Cancer Institute;02/21/2001, Vol. 93 Issue 4, p259 

    Evaluates the role of human papilloma virus's role (HPV) as a diagnostic tool. Establishment of the link between HPV and cervical cancer; Focus on high-risk women; Determination of best management strategies.

  • Interest of Human Papillomavirus DNA quantification and genotyping in paired cervical and urine samples to detect cervical lesions. Ducancelle, A.; Legrand, M.; Pivert, A.; Veillon, P.; Guillou-Guillemette, H.; Brux, M.; Beby-Defaux, A.; Agius, G.; Hantz, S.; Alain, S.; Catala, L.; Descamps, P.; Postec, E.; Caly, H.; Charles-Pétillon, F.; Labrousse, F.; Lunel, F.; Payan, C. // Archives of Gynecology & Obstetrics;Aug2014, Vol. 290 Issue 2, p299 

    Background: Cervical cancer is caused by persistent infection with high-risk human papillomavirus (HR-HPV). Conventional human papillomavirus (HPV) testing requires cervical sampling. However, vaginal and urine self-sampling methods are more acceptable for patients and result in increased...

  • Primary screening with HPV DNA testing feasible in some women.  // Hem/Onc Today;2/25/2009, Vol. 10 Issue 4, p27 

    The article discusses research being done on the use of primary human papillomavirus (HPV) deoxyribonucleic acid (DNA)-based screening with cytology triage and repeat HPV DNA testing for cervical screening, published in the 2009 issue of the "Journal of the National Cancer Institute."

  • FDA Approves HPV Test for Cervical Screening. Wang, Linda // JNCI: Journal of the National Cancer Institute;5/7/2003, Vol. 95 Issue 9, p644 

    Announces the U.S. Food and Drug Association's approval of the human papillomavirus DNA test as a primary screening tool for cervical cancer. Permission of the HPV DNA test to be used in combination with a Pap smear.

  • Fluctuations in prevalence of cervical human papillomavirus in women frequently sampled during a single menstrual cycle. van Ham, M.A.P.C.; Melchers, W.J.G.; Hanselaar, A.G.J.M.; Bekkers, R.L.M.; Boonstra, H. // British Journal of Cancer;8/12/2002, Vol. 87 Issue 4, p373 

    In the last few years much attention has been focused on the implementation of human papillomavirus detection in population based screening programmes to identify women at risk for cervical cancer. Short-term fluctuations in prevalence of human papillomavirus were investigated within a single...

  • Patient-collected vaginal specimens for HPV testing.  // Africa Health;Mar2012, Vol. 34 Issue 3, p58 

    The article focuses on a clinical trial in Mexico which reveals the benefit of human papillomavirus DNA (HPV DNA) testing of self-collected vaginal specimens in the detection of cervical cancer.

  • Adding HPV test to pap smears improves cervical screenings. Fuerst, Mark L. // Dermatology Times;Feb2000, Vol. 21 Issue 2, p37 

    Reports the use of human papillovirus (HPV) tests and pap smears for cervical cancer screening in Chicago, Illinois. Comparison of the sensitivity of cytology and HPV tests; Use of imiquimoid as topical treatment for cervical dysplasia; Linkage of smoking with HPV infection; Correlation between...

  • Primary HPV screening preferred in Europe.  // PharmacoEconomics & Outcomes News;3/17/2012, Issue 649, p4 

    The article reports on a study which advised European countries to consider switching from primary cytology to human papillomavirus (HPV) screening for cervical cancer.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics